Last 107.00 INR
Change Today -3.25 / -2.95%
Volume 725.0
TMCH On Other Exchanges
Symbol
Exchange
Natl India
As of 3:37 AM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

themis medicare ltd (TMCH) Snapshot

Open
106.10
Previous Close
110.25
Day High
108.40
Day Low
105.05
52 Week High
07/7/14 - 122.90
52 Week Low
08/20/13 - 40.00
Market Cap
861.4M
Average Volume 10 Days
7.4K
EPS TTM
-41.97
Shares Outstanding
8.1M
EX-Date
07/20/11
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for THEMIS MEDICARE LTD (TMCH)

Related News

No related news articles were found.

themis medicare ltd (TMCH) Related Businessweek News

No Related Businessweek News Found

themis medicare ltd (TMCH) Details

Themis Medicare Limited manufactures and markets pharmaceutical products in India and internationally. The company offers active pharmaceutical ingredients; and formulations in dosage forms for various therapeutic areas, such as anti tuberculosis, anti malarial, anesthetics, anti infective, anti hemorrhoidal, cardiology, pain management, anti osteoporotic, nutritional supplement, antihistaminics, and haemostatic agents, as well as respiratory disorders. It also provides generics, including oral solids and liquids, injectables, and topical preparations. The company was formerly known as Themis Chemicals and changed its name to Themis Medicare Limited in 2001. Themis Medicare Limited was founded in 1969 and is headquartered in Mumbai, India.

Founded in 1969

themis medicare ltd (TMCH) Top Compensated Officers

Managing Director, Chief Executive Officer, M...
Total Annual Compensation: 4.9M
Deputy Managing Director, Member of Executive...
Total Annual Compensation: 4.8M
Compensation as of Fiscal Year 2013.

themis medicare ltd (TMCH) Key Developments

Themis Medicare Ltd Commences Production, Marketing and Sales of Aquadol Spass 1 ml Injection

Themis Medicare Ltd. commenced the production, marketing and sales of Aquadol spass 1 ml Injection. Aquadol Injection is used by Urologist, Gastroenterologist, General Surgeon, General Practitioner and various faculties of Medical practitioners. It is mainly used by medical professionals for treating patients suffering from colic pain and spasm. Hence, the product has been widely needed by medical professionals in India. Themis also plans to come up with oral tablet formulation under the name of Aquadol tablet in coming days. The product also has an export potentiality & licensing opportunity.

Themis Medicare to Stop Operations of its Wholly Owned Foreign Subsidiary HIDPUL Kft, Hungary

Themis Medicare will stop operations of its wholly owned foreign subsidiary HIDPUL Kft, Hungary with immediate effect due to no activity in the said subsidiary. The board of directors at its meeting held on May 14, 2014 has approved for the same. The above is however subject to following rules in the country of incorporation that is Hungary.

Themis Medicare Ltd. Reports Audited Standalone Earnings Results for the Fourth Quarter and Audited Standalone and Consolidated Earnings Results for the Full Year Ended March 31, 2014

Themis Medicare Ltd. reported audited standalone earnings results for the fourth quarter and audited standalone and consolidated earnings results for the full year ended March 31, 2014. For the quarter, on standalone basis, the company reported net sales/income from operations (net of excise duty) of INR 306.979 million compared to INR 229.890 million a year ago. Profit from operations before other income, financial costs & exceptional items was INR 11.287 million compared to loss from operations before other income, financial costs & exceptional items if INR 5.676 million a year ago. Loss from ordinary activities before tax was INR 2.306 million compared to INR 44.060 million a year ago. Net profit was INR 0.615 million or INR 0.07 per diluted share before and after extraordinary items compared to net loss of INR 43.084 million or INR 4.87 per diluted share before and after extraordinary items for the same period a year ago. For the year, on standalone basis, the company reported net sales/income from operations (net of excise duty) of INR 1,668.481 million compared to INR 14,393.30 a year ago. Profit from operations before other income, financial costs & exceptional items was INR 127.013 million compared to INR 34.517 million a year ago. Profit from ordinary activities before tax was INR 11.418 million compared to loss from ordinary activities before tax INR 85.168 million a year ago.Net profit was INR 15.311 million or INR 1.73 per diluted share before and after extraordinary items compared to net loss of INR 81.262 million or INR 9.18 per diluted share before and after extraordinary items for the same period a year ago. For the year, on consolidated basis, the company reported net sales/income from operations (net of excise duty) of INR 1,894.494 million compared to INR 1,682.515 a year ago. Profit from operations before other income, financial costs & exceptional items was INR 149.192 million compared to INR 78.899 million a year ago. Profit from ordinary activities before tax was INR 36.576 million compared to loss from ordinary activities before tax INR 40.459 million a year ago. Net profit was INR 23.458 million or INR 2.65 per diluted share before and after extraordinary items compared to net loss of INR 63.175 million or INR 7.85 per diluted share before and after extraordinary items for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TMCH:IN 107.00 INR -3.25

TMCH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TMCH.
View Industry Companies
 

Industry Analysis

TMCH

Industry Average

Valuation TMCH Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THEMIS MEDICARE LTD, please visit www.themismedicare.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.